aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Argenx is a biotechnology company focused on developing innovative antibody-based therapies for cancer and autoimmune diseases. The company leverages its proprietary technology and expertise to design and develop a robust pipeline of treatments, aiming to address unmet medical needs and improve patient outcomes.
Argenx has achieved significant milestones, including the development of multiple clinical-stage therapies and partnerships with leading pharmaceutical companies. Its impactful work in antibody therapeutics has garnered attention and investment from notable industry figures and investors.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Antibody Therapies
Technology
Biotech
Tags
SaaS
Model Types
Recurring
Revenue Type(s)
Healthcare
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was argenx founded?
argenx was founded in 2008.
Where is argenx’s headquarters located?
argenx’s headquarters is located in Boston, MA, US.
When was argenx’s last funding round?
argenx’s most recent funding round was for $979.6M (USD) in July 2023.
How many employees does argenx have?
argenx has 1219 employees as of Feb 10, 2024.
How much has argenx raised to-date?
As of July 05, 2023, argenx has raised a total of $3.4B (USD) since Jul 19, 2023.
Add Comparison
Total Raised to Date
$3.4B
USD
Last Update Jul 19, 2023
Last Deal Details
$979.6M
USD
Jul 19, 2023
Post Ipo Equity
Total Employees Over Time
1219
As of Feb 2024
argenx Address
33 Arch Street
suite 3201
Boston,
Massachusetts
02110
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts